slv-306 has been researched along with Heart-Failure* in 3 studies
1 review(s) available for slv-306 and Heart-Failure
| Article | Year |
|---|---|
[Physiological and pathophysiological roles of the endothelin converting enzymes].
Topics: Animals; Aspartic Acid Endopeptidases; Benzazepines; Benzofurans; Drug Design; Endothelin-Converting Enzymes; Glycopeptides; Heart Failure; Humans; Hypertension; Metalloendopeptidases; Mice; Mice, Knockout; Myocardial Infarction; Organophosphonates; Phenylalanine; Tetracyclines; Tetrazoles | 2004 |
1 trial(s) available for slv-306 and Heart-Failure
| Article | Year |
|---|---|
Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure.
SLV306, a potent neutral endopeptidase (NEP) inhibitor with additional endothelin-converting enzyme (ECE)-inhibitory activity, in doses of 200, 400, and 800 mg reduced pulmonary and right atrial pressures, although there was not a clear dose response. Systemic blood pressure, heart rate, and cardiac output were unaffected. SLV306 increased plasma natriuretic peptides and big endothelin-1 levels in a dose-dependent manner, confirming NEP and ECE inhibition. The combined inhibition of NEP and ECE may be useful in heart failure by reducing right and left cardiac filling pressures. Topics: Aged; Aspartic Acid Endopeptidases; Benzazepines; Blood Pressure; Cardiac Output; Endothelin-Converting Enzymes; Female; Heart Failure; Heart Rate; Humans; Male; Metalloendopeptidases; Middle Aged; Neprilysin; Pulmonary Artery; Pulmonary Wedge Pressure | 2004 |
1 other study(ies) available for slv-306 and Heart-Failure
| Article | Year |
|---|---|
Endothelins are potent vasoconstrictors, and much more besides.
Topics: Aspartic Acid Endopeptidases; Benzazepines; Benzhydryl Compounds; Benzofurans; Endothelin Receptor Antagonists; Endothelin-1; Endothelin-Converting Enzymes; Endothelins; Enzyme Inhibitors; Heart Failure; Humans; Metalloendopeptidases; Organophosphonates; Pyrimidines; Vascular Diseases; Vasoconstrictor Agents | 2000 |